ANDEXXA: The First and Only FDA-approved Agent for Reversal of FXa Inhibitor Activity in Patients With Life-threatening or Uncontrolled Bleeding

Tuesday, August 2nd, 2022 | 11:00 AM - 12:00 PM CT

This program will discuss the burden of life-threatening bleeds related to FXa inhibitors, and focus on the mechanism of action, efficacy, and safety of a reversal agent indicated for patients treated with anticoagulants who have life-threatening bleeding.

Learning Points:
  • The Burden of Life-threatening Bleeds Related to FXa Inhibitors
  • Mechanistic Rationale for the Reversal of Anti-FXa Activity
  • Clinical Trials Evaluating the Efficacy and Safety of ANDEXXA in the Reversal of Apixaban or Rivaroxaban
  • The Real-world Use of ANDEXXA In the Reversal of Apixaban or Rivaroxaban


Dr. James B. Groce III (1x1) - Sarah Simon

James B. Groce III, PharmD, CACP

Professor at Campbell University College of Pharmacy & Health Sciences, Clinical Assistant Professor of Medicine, UNC School of Medicine, Clinical Pharmacy Specialist-Anticoagulation, Cone Health, Greensboro, NC